Literature DB >> 22509819

Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia.

Chris Kenyon, Sipho Mfolozi, Roland Croxford, Robert Colebunders, Karen Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22509819      PMCID： PMC3522823          DOI： 10.1111/j.1365-2125.2012.04299.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  "Chasing the dragon"--heroin-associated spongiform leukoencephalopathy.

Authors:  Tareq Kass-Hout; Omar Kass-Hout; M Ziad Darkhabani; Maxim Mokin; Bijal Mehta; Vladan Radovic
Journal:  J Med Toxicol       Date:  2011-09

Review 2.  A systematic review of the psychiatric side-effects of efavirenz.

Authors:  Christopher A Kenedi; Harold W Goforth
Journal:  AIDS Behav       Date:  2011-11

3.  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Authors:  Z Desta; N V Soukhova; D A Flockhart
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

Review 5.  Toxic leukoencephalopathies.

Authors:  Laura M Tormoehlen
Journal:  Neurol Clin       Date:  2011-08       Impact factor: 3.806

6.  Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells.

Authors:  Ana Blas-García; Nadezda Apostolova; Daniel Ballesteros; Daniel Monleón; Jose M Morales; Milagros Rocha; Victor M Victor; Juan V Esplugues
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

7.  Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.

Authors:  Xia Wen; Jun-Sheng Wang; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2002-01       Impact factor: 2.953

8.  Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

Authors:  Luis F López-Cortés; Rosa Ruiz-Valderas; Pompeyo Viciana; Aristides Alarcón-González; Jesús Gómez-Mateos; Eva León-Jimenez; Maria Sarasanacenta; Yolanda López-Pua; Jerónimo Pachón
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Efavirenz in the therapy of HIV infection.

Authors:  Natella Y Rakhmanina; John N van den Anker
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

10.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

Authors:  Hiroyuki Gatanaga; Tsunefusa Hayashida; Kiyoto Tsuchiya; Munehiro Yoshino; Takeshi Kuwahara; Hiroki Tsukada; Katsuya Fujimoto; Isao Sato; Mikio Ueda; Masahide Horiba; Motohiro Hamaguchi; Masahiro Yamamoto; Noboru Takata; Akiro Kimura; Takao Koike; Fumitake Gejyo; Shuzo Matsushita; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Clin Infect Dis       Date:  2007-09-24       Impact factor: 9.079
View more
  3 in total

1.  Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.

Authors:  Eric H Decloedt; Phumla Z Sinxadi; Gert U van Zyl; Lubbe Wiesner; Saye Khoo; John A Joska; David W Haas; Gary Maartens
Journal:  J Antimicrob Chemother       Date:  2019-03-01       Impact factor: 5.790

2.  Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.

Authors:  Ebrahim Variava; Farai R Sigauke; Jennifer Norman; Modiehi Rakgokong; Petudzai Muchichwa; Andre Mochan; Gary Maartens; Neil A Martinson
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

3.  Efavirenz and neuropsychiatric effects.

Authors:  Mukesh Dheda
Journal:  South Afr J HIV Med       Date:  2017-04-24       Impact factor: 2.744
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.